Samsung Medical Center
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT03110328
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification
- First Posted Date
- 2017-04-10
- Last Posted Date
- 2018-09-20
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 4
- Registration Number
- NCT03106155
- Locations
- 🇰🇷
Samsung Medical center, Seoul, Korea, Republic of
Concurrent Chemo-proton Radiotherapy With or Without Resection and Spacer Insertion for Loco-regional Recurrence of Previous Irradiated Rectal Cancer
Not Applicable
- Conditions
- Previously Irradiated Recurrent Rectal Cancer
- Interventions
- Radiation: Concurrent chemo-proton therapy
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT03098108
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 29
- Registration Number
- NCT03086538
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT03086291
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Comparison of Clinical Outcomes of Toric Intraocular Lens
Not Applicable
Completed
- Conditions
- Astigmatism
- Interventions
- Device: Tecnis toric intraocular lensDevice: Precizon toric intraocular lens
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT03085901
Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT03082833
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 28
- Registration Number
- NCT03083210
- Locations
- 🇰🇷
Youngsuk Park, Seoul, Korea, Republic of
DEB Versus 2nd Generation DES in Patients With In-Scaffold Restenosis of Bioresorbable Vascular Scaffold
Not Applicable
Withdrawn
- Conditions
- Coronary Artery DiseaseCoronary Restenosis
- Interventions
- Device: PCI for in-bioresorbable scaffold stenosis
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Samsung Medical Center
- Registration Number
- NCT03074305
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Korean Coronary Bifurcation Stenting (COBIS) Registry III
Completed
- Conditions
- Coronary Bifurcation Lesion
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 2648
- Registration Number
- NCT03068494
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath